The case for & against
Bull & Bear analysis
Bearish
Shattuck Labs, Inc. (NASDAQ: STTK) is a biotechnology company dedicated to innovating immunotherapies aimed at treating cancers, notably through its lead candidate SL172154, which targets CD47 while activating CD40. The firm is positioned within the expanding oncology therapeutics landscape, focusing on unmet medical needs in conditions such as acute myeloid leukemia (AML) and platinum-resistant ovarian cancer (PROC). With a solid cash position and significant clinical trial activities, Shattuck is navigating emerging opportunities despite the competitive challenges present in the CD47 inhibition space.
Bull says
- ↑SL172154 showed 27% overall response rate in PROC vs 4% benchmark
- ↑$208M cash balance provides funding into 2029 for clinical programs
- ↑Shares rose 842% YTD with consensus target $13.88 (+85% upside)
- ↑High price momentum, strong liquidity, and robust institutional backing signal confidence
- ↑Initiating Phase 2b trial to expand SL172154 into new patient cohorts
- ↑Elevated book-to-price ratio indicates potential undervaluation
Bear says
- ↓Q2 2026 net loss $15.2M with zero revenue, burdening cash burn
- ↓CD47-targeting drugs have shown severe toxicity risks, including anemia
- ↓Negative growth revisions suggest worsening fundamentals ahead
- ↓Crowded CD47 space with multiple competitive setbacks may limit market share
- ↓R&D spend rose to $24.2M in Q3 2023, heightening leverage risk
- ↓Poor profitability and negative earnings yield raise sustainability concerns
Earnings Call · Q3 2023 · Mgmt. Guidance
Updated 08-17-2026bullish
Transcript signals
Bull points
- Yeah, we are expecting to enroll up to 70 patients. That 70 patients will include high, medium, and low. And we are working with Immunogen to benchmark what would be an interesting response rate and durability of response in each of those subgroups.
- Overall, we are encouraged by the emerging data from this combination cohort and look forward to updates with more patients and longer follow-up.
- Overall, we are encouraged by the growing body of data that validates the unique mechanism of action of 154 and its therapeutic potential to address the unmet needs of patients with AML and higher risk MDS.
Bear points
- many of these patients enrolled to the imagrolimab arms may have discontinued earlier or may have had dose interruptions in a way that could have impacted the top line readouts of that study
Read full transcript analysis ›